Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Danazol
Drug ID BADD_D00576
Description A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Indications and Usage For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Marketing Status approved
ATC Code G03XA01
DrugBank ID DB01406
KEGG ID D00289
MeSH ID D003613
PubChem ID 28417
TTD Drug ID D09IPV
NDC Product Code 38779-0174; 0555-0635; 0555-0633; 62135-477; 0527-1369; 71205-862; 0527-1392; 53104-7501; 71052-662; 62135-476; 62135-475; 0527-1368; 49452-2436; 71205-861; 49076-5201; 0555-0634
UNII N29QWW3BUO
Synonyms Danazol | Danazant | Panacrine | Danocrine | Ladogal | Cyclomen | Danatrol | Danol | Danoval | Norciden | Azol | Danazol-Ratiopharm | Danazol Ratiopharm
Chemical Information
Molecular Formula C22H27NO2
CAS Registry Number 17230-88-5
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin disorder23.03.03.0070.002361%Not Available
Sleep disorder19.02.04.001--Not Available
Spermatogenesis abnormal21.03.03.002--Not Available
Spermatozoa progressive motility abnormal13.20.04.011--Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.003541%
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Thrombocytopenia01.08.01.0020.004722%Not Available
Thrombosis24.01.01.006--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.0130.002361%Not Available
Vomiting07.01.07.0030.002361%
Vulvovaginal discomfort21.08.02.005--Not Available
Vulvovaginal dryness21.08.02.003--
Weight increased13.15.01.006--
Thyroxin binding globulin abnormal13.10.06.013--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Platelet count increased13.01.04.002--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Lipoprotein (a) abnormal13.12.01.016--Not Available
Nodule08.03.05.002--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Sex hormone binding globulin13.10.05.016--Not Available
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene